Skip to main content
MNPR
NASDAQ Life Sciences

Monopar Presents New Phase 3 Analyses Showing Greater Neurologic & Global Benefit for ALXN1840 in Wilson Disease

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$87.68
Mkt Cap
$587.374M
52W Low
$29.18
52W High
$105
52W Position info
200% above low
Off High info
16% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

MNPR has more than doubled off its 52-week low of $29.18.

Summary

Monopar Therapeutics announced new analyses from its Phase 3 trial for ALXN1840, showing greater neurologic and global clinical benefits in Wilson disease patients, further supporting its upcoming FDA submission.


Key Events · Product Development and Regulatory · MNPR

  • New Phase 3 Data Analyses

    Monopar presented new analyses from its Phase 3 FoCus trial for ALXN1840 in Wilson disease.

  • Superior Clinical Benefit

    The analyses demonstrated greater neurologic and global clinical benefit compared to standard of care in patients with neurologic symptoms.

  • Conference Presentation

    These findings will be presented at the 12th Congress of the European Academy of Neurology (EAN) from June 27-30, 2026.

  • NDA Submission Support

    The positive results further support the planned New Drug Application (NDA) submission to the FDA for ALXN1840 in mid-2026.


Analysis · MNPR · Life Sciences

This 8-K announces new, detailed analyses from the Phase 3 FoCus trial for ALXN1840 in Wilson disease, demonstrating superior neurologic and global clinical benefits compared to standard of care. These findings, to be presented at a major neurology conference, significantly strengthen the drug's profile and reinforce the company's planned mid-2026 NDA submission to the FDA.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNPR was trading at $87.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $587.4M. The 52-week trading range was $29.18 to $105.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNPR - Latest Insights

MNPR
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $69.15 info
Change: -$1.16 (-2%) info
Market Cap: $468.58M info
MNPR
Nov 12, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $69.15 info
Change: -$1.16 (-2%) info
Market Cap: $468.58M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $115.19
Real-time Price: $69.15 info
Change: -$46.05 (-40%) info
Market Cap: $468.58M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $114.46
Real-time Price: $69.15 info
Change: -$45.32 (-40%) info
Market Cap: $468.58M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $115.19
Real-time Price: $69.15 info
Change: -$46.05 (-40%) info
Market Cap: $468.58M info